• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Public Meeting on Sickle Cell Disease Patient-Focused Drug Development

On February 7, 2014, FDA conducted a public meeting on Patient-Focused Drug Development for sickle cell disease. FDA is interested in obtaining patients’ perspectives on the impact of sickle cell disease on daily life as well as the available therapies for sickle cell disease.

In addition to providing input at the public meeting, patient stakeholders are invited to provide their perspectives on the discussion questions through the public docket. The docket closes on April 8, 2014.



expertly curated content related to this topic